Combination treatment for advanced colorectal cancer after two prior therapies
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are physically able to take care of yourself (up and about, no bed rest needed).
- You have colorectal cancer that has spread and can no longer be removed with surgery.
- You have already tried two prior treatment plans, and the cancer still progressed.
- You have tumors in your lungs or liver that can be treated with a special type of radiation.
- You have not had immunotherapy before, and your tumor does not have certain genetic features (like MSI-H or BRAF mutation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
This trial studies a combination of three drugs — an immunotherapy (sintilimab), a blood vessel growth blocker (bevacizumab), and a chemotherapy helper (decitabine) — for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer when standard options have failed.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.